Coverage
AstraZeneca PLC said its experimental drug baxdrostat significantly lowered blood pressure in patients with a hard-to-treat form of hypertension, meeting the main goal of a late-stage trial.
AstraZeneca PLC and Daiichi Sankyo said their drug Datroway significantly improved survival for patients with an aggressive form of breast cancer in a late-stage study.
AstraZeneca PLC said its cancer drug Enhertu, developed with Daiichi Sankyo, showed a significant improvement over the standard treatment in a late-stage trial for patients with a high-risk form of early breast cancer.
AstraZeneca PLC on Monday announced plans to directly list its ordinary shares on the New York Stock Exchange, a move aimed at attracting a broader base of global investors and accessing deeper capital pools.
AstraZeneca PLC said its drug Koselugo won a key European regulatory backing for use in adults, a positive development for the company following recent setbacks in its drug pipeline.
AstraZeneca PLC said its drug Tezspire, developed with Amgen Inc., won a key European regulatory backing for a new use, a positive development for the company following recent trial setbacks.
Filings
| Filing | Date |
|---|---|
| Imfinzi recommended for EU approval for AEGEAN | 3 Mar 2025 |
| Total Voting Rights | 3 Mar 2025 |
| Enhertu recommended in EU in post-ET breast cancer | 28 Feb 2025 |
| Camizestrant improved PFS in 1L HR+ breast cancer | 26 Feb 2025 |
| Filing of Form 20-F with SEC | 19 Feb 2025 |
| Directorate Change | 18 Feb 2025 |
| Annual Financial Report | 18 Feb 2025 |
| Holding(s) in Company | 18 Feb 2025 |
| Final Results | 6 Feb 2025 |
| Imfinzi recommended for EU approval for LS-SCLC | 3 Feb 2025 |
| Total Voting Rights | 3 Feb 2025 |
| Enhertu approved in US for breast cancer post ET | 28 Jan 2025 |